The Italian severe/uncontrolled asthma registry (RItA): A 12-month clinical follow-up

• Published in: Respiratory medicine 2022-12, Vol.205, p.107030, Article 107030
• Main Authors: Maio, Sara, Murgia, Nicola, Tagliaferro, Sofia, Angino, Anna, Sarno, Giuseppe, Carrozzi, Laura, Pistelli, Francesco, Bacci, Elena, Paggiaro, Pier Luigi, Latorre, Manuela, Baldacci, Sandra, Viegi, Giovanni
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Adrenal Cortex Hormones - therapeutic use; Anti-Asthmatic Agents - therapeutic use; anti-IgE treatment; Asthma - diagnosis; Asthma - drug therapy; Asthma - epidemiology; Asthma control; Cross-Sectional Studies; Follow-Up Studies; Humans; Longitudinal patterns; Phenotypes; Registries; Registry
• ISSN: 0954-6111; 1532-3064
• DOI: 10.1016/j.rmed.2022.107030

follow-up studies on registries of severe/uncontrolled asthma (SUA) patients are scanty. to analyze baseline and follow-up characteristics of SUA patients and their longitudinal patterns. 180 adult patients (age ≥15 yrs) were investigated at baseline and 12-month follow-up through the Italian SUA registry (RItA). Latent transition analysis (LTA) was performed to detect cross-sectional SUA phenotypes and longitudinal patterns. Risk factors for longitudinal patterns were assessed through logistic regression. a significant/borderline improvement of asthma control outcomes in the last 2–4 weeks emerged at follow-up with respect to baseline for: daily activities limitations (Δ −16%), frequent diurnal symptoms (Δ −25%), uncontrolled asthma symptoms according to ACT (Δ −26%). Last 12-month use of oral corticosteroids was less frequent at follow-up than at baseline (Δ −25%). Health status improvement was confirmed by lung function test results. Through LTA, two longitudinal patterns were detected considering last 12-month control outcomes: “persistence/worsening” (53.9%), “under control/improvement” (46.1%). A lower likelihood of having “persistence/worsening” SUA was exhibited by patients under anti-IgE (OR 0.38, 95% CI 0.17–0.84) and inhaled corticosteroids-bronchodilator association treatment (OR 0.13, 95% CI 0.01–1.26, borderline value), while a higher likelihood was shown by older age at first asthma diagnosis (OR 1.04, 95% CI 1.01–1.07). the implementation of a SUA registry, the availability of patient-level data and the application of an innovative longitudinal analysis allowed to observe a general improvement in asthma control, one year after baseline, and a lower risk of SUA “persistence/worsening” in patients under anti-IgE and regular ICS-bronchodilator association use. •Registries collect information for preventive, diagnostic, therapeutic strategies.•Patient-level longitudinal data allowed to identify predictors of clinical patterns.•Regular review allows for thorough patients' clinical characterization and management.